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doi:10.1016/j.jtcvs.2007.01.085bjective: Patients with refractory acute cardiogenic shock and multisystem organ
ailure have a poor outcome with implantation of permanent ventricular assist
evices. We review our experience with the use of the CentriMag (Levitronix LLC,
altham, Mass) circulatory support system in such patients whose neurologic status
as uncertain.
ethods: From January 2004 to June 2006, 30 patients underwent CentriMag
irculatory support system placement at the University of Minnesota. Of these
atients, 12 were transferred from an outside hospital with refractory acute cardio-
enic shock requiring biventricular support; they are the focus of this study.
esults: Of our 12 study patients, 8 underwent successful bridging to the HeartMate
VE (Thoratec Corp, Pleasanton, Calif) ventricular assist device after biventricular
upport (mean support time of 9.4 days, range: 5–22 days). Another 2 patients
nderwent successful explantation (after 8 and 9 days); the remaining 2 patients died
after 4 days). Thus, the survival on CentriMag support, to either bridge or recovery,
as 83% (10/12). Of the 8 patients who subsequently underwent HeartMate im-
lantation, 5 also underwent a heart transplant within 6.9 months (range, 4.5-10
onths), another 2 are still awaiting a transplant, and 1 died of sepsis and right
entricular failure 3 days after HeartMate implantation. Thus, for our 12 study
atients, long-term survival was 75% at 1 month and 62.5% at 1 year.
onclusions: Our aggressive strategy in this group of patients involved early
perative intervention and implantation of biventricular support. By using this
trategy, we avoided the urgent placement of expensive long-term ventricular assist
evices in hemodynamically unstable patients with multisystem organ failure whose
eurologic status was uncertain until end-organ recovery and excellent hemody-
amic stability were achieved with the relatively inexpensive short-term CentriMag
irculatory support system. The excellent midterm outcomes in this group of
atients whose original prognosis was poor justify this therapeutic strategy.
efractory acute cardiogenic shock remains the leading cause of death in
patients hospitalized with myocardial infarction. Multicenter trials have
reported an early mortality rate of more than 50% in such patients despite
dequate and prompt revascularization.1,2 For many of these patients, mechanical
irculatory support as a bridge to transplantation remains the only means of survival.
remendous progress has been made in the management of acute cardiogenic shock
ith the use of mechanical assist devices.3-5 The increased applicability and excel-
ent results with left ventricular assist devices (LVADs) have revolutionized the
reatment options available for patients with end-stage heart failure.6-8 The success
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CSPf the Randomized Evaluation of Mechanical Assistance for
he Treatment of Congestive Heart Failure trial of destina-
ion therapy further opened a new door for patients ineligi-
le for a heart transplant.9
Patients whose survival is still poor are those in multi-
ystem organ failure (MSOF) secondary to acute cardio-
enic shock refractory to maximal medical therapy (includ-
ng the use of intraaortic balloon pump [IABP], multiple
notropes, and pressors). The only 2 options available for
uch patients are (1) ventricular support with mechanical
ssist devices or (2) extracorporeal membrane oxygenation
ECMO). For patients with MSOF who have had a prior
ardiac arrest or who have severe hemodynamic instability,
utcomes after permanent LVAD implantation are ex-
remely poor. The use of LVADs for these patients is
ontroversial. First, these patients often need biventricular
upport, the presence of which limits long-term options.
econd, the question arises as to whether these patients
hould have a permanent device placed at the time of
resentation. The common combination of MSOF and un-
ertain neurologic status, along with the uncertainty of
dequate social support (because of the unavailability of
dequate time to complete such an evaluation), clouds the
ransplant candidacy of these patients. In addition, the major
nd lengthy surgery required for permanent LVAD implan-
ation in patients with significant hemodynamic instability,
oagulopathy, and liver and renal failure significantly in-
reases postoperative morbidity and mortality.
Clearly, there is an increased role for temporary circula-
ory support in such patients. Questions remain as to the
deal device, the optimal duration of support, and the ideal
iming to bridge these patients to a permanent device. A
isadvantage with temporary support is that multiple sur-
eries and the need for anticoagulation are required, both of
hich have their attendant complications. An advantage, at
east in patients in whom MSOF does not resolve and whose
eurologic function recovers poorly, is that permanent
VAD implantation is avoided.
We developed an algorithm at the University of Minne-
ota for initiating temporary circulatory support in patients
Abbreviations and Acronyms
ACT  activated clotting time
ECMO extracorporeal membrane oxygenation
GCS  Glasgow Coma Scale
IABP  intraaortic balloon pump
LVAD  left ventricular assist device
MSOF multisystem organ failure
RVAD right ventricular assist device
SCr  serum creatinine
VAD  ventricular assist deviceith refractory acute cardiogenic shock and MSOF who i
52 The Journal of Thoracic and Cardiovascular Surgery ● Auguave contraindications to permanent ventricular assist de-
ice (VAD) implantation at the time of presentation. We
erformed a retrospective study of all patients from January
004 to June 2006 who were transferred to our institution
rom outside institutions with acute cardiogenic shock re-
ractory to maximal medical therapy and who then under-
ent temporary CentriMag (Levitronix LLC, Waltham,
ass) circulatory support at our institution. The objectives
f our study were to (1) describe the benefit of CentriMag
upport in these patients, (2) describe postoperative end-
rgan recovery and neurologic recovery after temporary
entriMag support, (3) identify the timing of permanent
evice implantation, and (4) describe overall outcomes,
ncluding postoperative complications and survival to per-
anent LVAD implantation, heart transplantation, or device
xplant.
aterials and Methods
atients
rom January 2004 to June 2006, 30 patients underwent temporary
entriMag circulatory support at the University of Minnesota. Of
hese 30 patients, 12 were transferred from outside hospitals with
efractory acute cardiogenic shock, despite IABP, multiple inotropes
nd pressors, and MSOF. Of the 12 patients, 2 were transferred to our
nstitution on Bio-Medicus pumps (Medtronic Bio-Medicus Inc, Min-
eapolis, Minn) because they could not be weaned off cardiopulmo-
ary bypass after emergency coronary artery bypass surgery for acute
yocardial infarction. Both of these patients had an episode of
ardiac arrest in the catheterization laboratory at the outside insti-
ution and were urgently taken for bypass surgery. All 12 patients
ere supported with the biventricular CentriMag system and thus
omprise our study group. The remaining 18 patients underwent
entriMag placement for other indications, including posttrans-
lant allograft failure, right ventricular failure after permanent
VAD, and postcardiotomy shock.
entriMag System
he CentriMag system is composed of a single-use centrifugal
lood pump, a motor, a console, and a flow probe.10,11 The system
s based on the “bearingless motor” technology, which combines
he drive, magnetic bearing, and rotor function into a single unit.
he motor generates the magnetic bearing force that levitates the
mpeller in the pump housing while also generating the torque
ecessary to produce unidirectional flow. The characteristic of the
agnetic levitation is the absence of bearings and seals, resulting
n minimal friction and minimal heat generation in the blood path.
he rotor surface is uniformly washed, which minimizes the area
f blood stagnation and turbulence in the pump. To reduce shear
orces and hemolysis, the mechanical gaps in the pump are greater
han 0.6 mm. This system can produce flows up to 10 liters per
inute under normal physiologic conditions and has a priming
olume of 31 mL.
urgical Techniques
ll 12 study patients underwent urgent cardiac surgery at ournstitution through a median sternotomy for initiation of biven-
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Pricular CentriMag support. After anticoagulation based on acti-
ated clotting time (ACT)-guided heparinization, the patients un-
erwent cardiopulmonary bypass. Aminocaproic acid (Amicar,
mgen Inc, Thousand Oaks, Calif) was administered to all
atients. If time permitted, the cannulas used for aortic and right
trial cannulation for cardiopulmonary bypass were tunneled
hrough subcostal incisions (because these same cannulas
ould be used later for the LVAD outflow and the right ven-
ricular assist device [RVAD] inflow). The urgent need for
ardiopulmonary bypass was based on these patients’ hemody-
amic instability. Further, decompression of the heart with
ardiopulmonary bypass facilitated the ease of subsequent
lacement of the left atrial and pulmonary artery cannulas (also
laced after subcostal tunneling).
The aortic and pulmonary artery cannulas were placed through
ouble-layer purse-string 3-0 Tevdek sutures with multiple
ledgets. Both atrial cannulas were placed through double-layer
urse-string 2-0 Tevdek sutures with multiple pledgets. For addi-
ional stability, multiple 2-0 Tevdek ties were placed around the
annula and the snares. The cannula of choice for aortic and
ulmonary artery cannulation was the Medtronic elongated 1-piece
rterial cannula (20F or 22F). The choice of cannula for atrial
annulation was an angled venous cannula (24F or 28F). Note that
he choice of cannula size was customized to the patient’s body
urface area.
The CentriMag pump heads and tubing were prepared and
rimed extracorporeally. The tubing was then divided within the
perating field and appropriately connected to each cannula, care-
ully avoiding any air in the system. LVAD support was then
nitiated, followed by RVAD support. The speed of each pump
as increased to provide a cardiac index of greater than 2.2 to 2.4
/min. Once satisfactory flows were achieved, protamine was
iven and meticulous hemostasis was performed. The sternotomy
as closed in the usual fashion with surgical steel wires, and the
atient was returned to the intensive care unit. In case of coagu-
opathy with ongoing mediastinal bleeding, the patient’s chest was
acked and left open.
nticoagulation
eparin was only started once the chest tube output was less than
0 mL per hour (usually  24 hours) to maintain an ACT of 160
o 180 seconds for the first 4 days. After day 4, heparin dosing was
ncreased to maintain an ACT of 180 to 200 seconds.
ostoperative Care
nd-organ function was closely monitored. Appropriate enteral or
arenteral nutrition was also initiated. Once patients had stable
emodynamics on CentriMag support with improving end-organ
unction, they were weaned off sedation and allowed to awaken to
ssess their neurologic function. If the neurologic function re-
ained uncertain, a neurologic consultation was obtained along
ith appropriate tests (computed tomography scan, electroenceph-
logram). If neurologic function and prognosis were poor, the
amily was consulted and a decision was made regarding with-
rawal of support (Figure 1).
Given evidence of neurologic recovery, a decision was made to
1) continue with CentriMag support, (2) wean the patient off
entriMag support, (3) evaluate the patient for transplantation, and r
The Journal of Thoracic4) bridge the patient to permanent LVAD implantation. The
iming for the decision also depended on renal, hepatic, and
espiratory recovery and on confirmation of the absence of any
nfection. Within 3 to 5 days after CentriMag support began,
chocardiography was performed to evaluate left and right ven-
ricular recovery. This echocardiography assessment was made
uring a period of gradual reduction in CentriMag flow and ade-
uate heparinization. If left and right ventricular recovery was
resent, then explantation was performed once renal, hepatic, and
espiratory function returned to normal (Figure 1).
If evidence of ventricular recovery was not seen within 1 week
fter CentriMag support began, a decision was made on eligibility
or implantation of a HeartMate XVE LVAD (Thoratec Corp,
leasanton, Calif) as either bridge or destination therapy. During
eartMate implantation, the existing aortic and right atrial cannu-
as were used for cardiopulmonary bypass after CentriMag support
as discontinued. Aprotinin was used during HeartMate implan-
ation. A preperitoneal (n  5) or an intraperitoneal (n  3)
eartMate implantation was performed. After weaning from car-
iopulmonary bypass, LVAD flow was initiated and the patients
ere supported with appropriate inotropes or pressors as
ecessary.
tatistical Analysis
ifferences in hemodynamic and end-organ function were com-
ared using 1-way repeated analysis of variance. Survival esti-
ates were based on the Kaplan–Meier method and compared
sing log-rank statistics. All values are expressed as mean 
tandard error of the mean. All data were analyzed using the SAS
ystem software version 9.0 (SAS Institute, Inc, Cary, NC).
esults
atient Characteristics
n our study, the 12 patients who underwent temporary
iventricular CentriMag support were all male; their mean
ge was 57.9 9 years. The cause of cardiogenic shock was
cute myocardial infarction (n  10) or acute decompensa-
ion of chronic ischemic cardiomyopathy (n  2). The
verage duration of CentriMag support was 8 days (range
-22 days).
The patients’ hemodynamic characteristics and end-organ
unctional status before and on the last day of CentriMag
upport are summarized in Table 1. All 12 patients initially
ad evidence of severe biventricular failure and required
echanical ventilation and intravenous infusion of ino-
ropes and vasopressors. Eleven patients had IABPs
91.7%).
At the time CentriMag support began, 9 patients (75%)
ere unresponsive, with a Glasgow Coma Scale (GCS)
core of 3; 2 patients had significantly impaired responsive-
ess, with a GCS score of 7; and 1 patient had a GCS score
f 11. The mean arterial pressure was 67.0  9.8 mm Hg,
nd the mean central venous pressure was 17.1  3.9 cm
2O. Eleven patients (91.7%) had evidence of significantenal dysfunction with a serum creatinine (SCr) concentration
and Cardiovascular Surgery ● Volume 134, Number 2 353
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CSPf 2 mg/dL or greater (mean, 2.67 0.9 mg/dL) and a mean
stimated glomerular filtration rate of 44.5  26 mL/min/
.73 m2). All patients had abnormalities in liver function.
en patients (83.3%) had evidence of systemic inflamma-
ion with leukocytosis greater than 10  103/L; for all 12
atients, the mean white blood cell count was 15.2  7.4 
03/L.
hort-term Survival
f the 12 patients, 8 underwent successful bridging to Heart-
ate implantation after CentriMag support (mean support time
.4 days; range 5-22 days); 2 patients underwent successful
xplantation (after 8 and 9 days); and the remaining 2 patients
ied (after 4 days of support). The 2 patients who died both had
entriMag support withdrawn because of severe neurologic
njury (possibly preexisting). Thus, the survival on CentriMag
upport, to either HeartMate implantation or recovery, was
3% (10/12), with an overall mean circulatory support time of
days (range 4-22 days). The probability of survival on
entriMag support was 83% 7 days after implantation and
Figure 1. Algorithm depicting the management of pat
acute cardiogenic shock with MSOF. IABP, Intraaorti
encephalogram.3% 14 days after implantation. o
54 The Journal of Thoracic and Cardiovascular Surgery ● Auguong-term Survival
f the 8 patients who subsequently underwent HeartMate
mplantation, 5 also underwent a heart transplant within 6.9
onths (range 4.5-10 months); another 2 patients are still
waiting a transplant at 51 and 77 days after implantation,
nd 1 patient died of sepsis and right ventricular failure 3
ays after implantation. Of the 5 heart transplant recipients,
are still alive at 18.6 months posttransplant (range 15-23
onths) and 1 died of sepsis 3 days posttransplant surgery.
hus, the survival after HeartMate implantation to a heart
ransplant was 62% (5/8). The 2 patients who underwent
uccessful explantation (after 8 and 9 days of CentriMag
upport) were free of heart failure at 18.6 months follow-up.
Thus, the total long-term survival benefit of CentriMag
upport (as either “bridge-to-bridge” or “bridge-to-recovery”
herapy) in our 12 patients was 75% at 1 month and 62.5%
t 1 year, as shown in Figure 2.
ost-CentriMag Support Measurements
o assess changes in hemodynamic, neurologic, and end-
transferred from outside institutions with refractory
lloon pump; CT, computed tomography; EEG, electro-ients
c bargan function, we compared hemodynamic parameters,
st 2007
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Paboratory markers of end-organ function, and neurologic
unction using the GCS before and on the last day of
entriMag support. The last day was the day of permanent
eartMate implantation, or CentriMag explantation, or day
f death.
igure 2. Kaplan–Meier survival after CentriMag (Levitronix LLC,
ABLE 1. Hemodynamic characteristics and end-organ fun
LC, Waltham, Mass) support
Before CentriM
(N 
emodynamic characteristics (mean)
ystolic blood pressure (mm Hg) 90.3
iastolic blood pressure (mm Hg) 55.4
rterial pressure (mm Hg) 67.0
eart rate (beats/min) 92.1
ystolic pulmonary artery pressure (mm Hg) 44.3
iastolic pulmonary artery pressure (mm Hg) 27.8
ean pulmonary artery pressure (mm Hg) 52.4
entral venous pressure (cmH2O) 17.1
aboratory parameters (mean) pH 7.38
hite blood count (cells  103/L) 15.2
emoglobin (mg/dL) 11.1
ematocrit (%) 32.3
latelet count (cells  103/L) 133.7
lood urea nitrogen (mg/dL) 42.5
Cr  2 mg/dL 11 (91.
Cr (mg/dL) 2.67
stimated SCr clearance (mL/min/1.73 m2) 44.5
ST 937
LT 962
LP 65.7
otal bilirubin 1.96
lbumin 2.5
NR 2.0
TT 73.2
NOVA, Analysis of variance; SCr, serum creatinine; AST, aspartate amin
nternational normalized ratio; PTT, prothrombin time.ealtham, Mass) support.
The Journal of ThoracicHemodynamic changes. Most measures of left ventric-
lar function and right heart function improved on
entriMag support (Table 1). Six patients (50%) were able
o be completely weaned off inotropes while on CentriMag
upport.
Neurologic recovery. Patients on CentriMag support
ad marked improvement in neurologic status. On the last
ay of CentriMag support, neurologic function had signifi-
antly improved in 7 of 9 patients who initially were unre-
ponsive with a GCS score of 3; of those 7 patients, 4
ompletely recovered. In 2 patients with moderately de-
reased responsiveness and an initial GCS score of 7, neu-
ologic function returned to near-normal with a GCS score
reater than 11. The GCS score remained unchanged in the
patient with initially intact neurologic function.
End-organ function. Significant changes in renal and he-
atic function occurred on CentriMag support (Table 1). Of the
1 patients whose initial SCr was greater than 2 mg/dL, 5 had
mprovement in renal function, with a decline in SCr of less
han 2 mg/dL (45%). Markers of acute hepatic injury, such as
nal status before and at the end of CentriMag (Levitronix
pport On last day of CentriMag support
(N  12)
One-way ANOVA
P value
104.1 19.5 .06
66.1 18.4 .16
78.7 13.7 .03
82.7 14.4 .29
33.0 8.1 .07
18.7 4.0 .03
48.1 9.2 .43
13.7 2.7 .05
7.36 0.07 .48
13.2 6.8 .99
10.1 1.0 .20
29.8 3.4 .33
116.9 69.9 .52
49.4 31.4 .47
5 (41.7%)
2.27 1.3 .32
56.5 39.5 .12
251 292 .23
87 94 .05
103.7 67.9 .04
2.85 2.8 .008
2.7 0.3 .38
1.9 1.2 .90
59.7 31.9 .31
sferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; INR,ctio
ag su
12)
13.2
12.2
9.8
28.8
12.2
8.4
9.0
3.9
0.12
7.4
2.5
7.4
69.9
16.3
7%)
0.9
26.0
1123
1201
22.6
1.1
0.5
1.6
39.8
otranlevations in liver enzymes, significantly decreased.
and Cardiovascular Surgery ● Volume 134, Number 2 355
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CSPCentriMag performance. Adequate circulatory support
as achieved in all 12 patients to maintain a cardiac index
reater than 2.2 liters per minute. Both left and right
entriMag pumps were run between 2500 and 3300 rpm to
rovide a flow of 4 to 6 liters per minute. Arterial pulse was
sually absent for the first 48 hours. With LV recovery,
ulsatility returned, suggestive of native LV ejection. No
ump failure occurred because of thrombosis or any other
echanical causes. One patient who received heparin for
ardiopulmonary bypass had evidence of extensive throm-
us in the LVAD outflow tubing within 30 minutes after
entriMag support began; this patient was diagnosed with
eparin-induced thrombocytopenia. After administration of
ivalirudin, the tubing and CentriMag pump were ex-
hanged and functioned well subsequently.
iscussion
n most of our 12 patients with acute cardiogenic shock,
ith MSOF and severe neurologic dysfunction, we showed
hat temporary biventricular CentriMag circulatory support
mproved end-organ function and allowed for full neuro-
ogic recovery; 80% of them became acceptable candidates
or HeartMate implantation. Our approach allowed for re-
overy of many patients otherwise ineligible for HeartMate
VAD implantation, with an excellent 1-year survival.
As the use of mechanical circulatory support in patients
ith heart failure increases, and as options increase for
echanical assistance, the indications for implantation of
ach device needs to be clarified. Although individual pa-
ients continue to benefit from this life-saving technology,
he cost–benefit ratio of implantable support therapy cer-
ainly does not justify its use in all potential recipients.
dentification of preoperative variables that accurately pre-
ict risk is important for planning and devising management
trategies, especially in patients with medical challenges. A
olumbia-Presbyterian Hospital study identified the follow-
ng risk factors for increased operative mortality: mechan-
cal ventilation, postcardiotomy shock, previous LVAD,
levated central venous pressure, and elevated prothrombin
ime.12,13 The presence of those factors (score  5) was
ssociated with an almost 50% postoperative mortality rate.
ote that their screening scale did not even take into ac-
ount the patient’s neurologic status. In addition to the
remendous impact on financial resources and logistics, the
motional impact on the family when support is withdrawn
rom a patient who is brain-dead or has severe neurologic
njury is devastating.
We do not agree with the concept that a long-term or
ermanent device should always be placed in an urgent
ituation.14,15 In our experience, rapid stabilization of the
atient was of primary importance: Adequate systemic per-
usion must be provided with minimal complications, neu-
ologic function must be ascertained, and end-organ func- C
56 The Journal of Thoracic and Cardiovascular Surgery ● Auguion must be allowed to recover. Screening scales suggest
hat permanent LVAD implantation in patients with MSOF
as an unacceptably high mortality rate.13 Even though
emodynamic stability is fairly comparable after short-term
nd permanent LVAD implantation, there will be a cohort
f patients who have irreversible neurologic injury and in
hom placement of a permanent LVAD is simply a waste
f resources, with no gain achieved.
Two important questions must be considered in patients
ith acute cardiogenic shock, MSOF, a prior cardiac arrest,
nd severe neurologic dysfunction. First, how do we iden-
ify the patient who will benefit from temporary circulatory
upport? Mortality rates after permanent LVAD insertion in
his group are greater than 50%. Second, what modality of
emporary circulatory support should be used? This is a
elatively unresolved issue. Short-term VADs include the
idely used Abiomed BVS 5000 (Abiomed Inc, Danvers,
ass) and Bio-Medicus systems and the more recently
ntroduced CentriMag system.10,16-18 In addition, ECMO is
lso useful.19-21 Samuels and colleagues16 reported a 31%
ospital discharge rate for patients with acute cardiac failure
n the Abiomed. The many advantages of the Abiomed
ave led to an extensive experience with it. However, dis-
dvantages include the need for performing anastomoses for
ortic and pulmonary artery cannulation, with resultant
leeding complications and the need for pump exchanges at
ess than 1-week intervals.
Although ECMO has multiple advantages, major disad-
antages include a limited duration of support, a high inci-
ence of complications with increasing duration of support,
nd the need for fairly stringent anticoagulation. In addition,
CMO requires a dedicated team of personnel to allow for
ts safe use. Pagani and colleagues,19 of the University of
ichigan, reported a 43% 1-year survival in patients with
ardiogenic shock with either a prior cardiac arrest or severe
emodynamic instability who were initially treated with
CMO as a bridge to permanent LVAD implantation. In
ontrast, a Columbia-Presbyterian Hospital study reported a
0-day survival of 56% in 46 patients who underwent
rgent HeartMate LVAD implantation after being trans-
erred from outside institutions with cardiogenic shock.22
In our study, by using CentriMag support in 12 patients
ith refractory acute cardiogenic shock and MSOF who
ere transferred from an outside hospital, we achieved a
0-day survival of 75%. The ease of use of the CentriMag
ystem allowed for rapid assessment of ventricular recov-
ry, weaning, and potential explantation (as we were able to
chieve in 2 patients). Its “user-friendly” nature is borne out
y the fact that virtually any cannulas (including those used
or routine cardiopulmonary bypass) can be used. In addi-
ion, 2 patients who were transferred with Bio-Medicus
entrifugal pumps were easily converted to extracorporeal
entriMag support. The CentriMag system’s durability is
st 2007
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Plso much greater than that of any other temporary circula-
ory assist device currently available.
In a study from Innsbruck, Hoefer and colleagues23 re-
orted excellent results with ECMO support in patients with
ardiogenic shock. However, they reported a 50% mortality
ate in patients with ECMO support who were bridged to
ermanent VAD implantation; most deaths due to MSOF
ith sepsis. The limited durability of ECMO (the risk of
omplications increases with increased duration of ECMO)
ay have led to the institution of permanent VAD support
hile patients still had unresolved end-organ dysfunction.
Our policy at the University of Minnesota for such pa-
ients allows for recovery of renal, hepatic, and respiratory
ystems during the support period. These patients can also
e weaned off the ventilator and even extubated if their
ondition warrants. While the patient is intubated, nursing
nd physiotherapy staff are encouraged to mobilize the
atient and perform some rehabilitative therapy. We have
lso instituted an aggressive nutritional program (preferably
nteral) during CentriMag support. Although we have not
obilized patients out of bed, they are awake and can
ollow commands, which allows us to also perform limited
hysical therapy.
Additional advantages with CentriMag support include
he absence of stringent requirements for anticoagulation.
any patients who require urgent mechanical circulatory
upport are receiving clopidogrel or glycoprotein IIb/IIIa
nhibitors; as a result, they have significant postoperative
leeding that is often refractory to correction of coagulopa-
hy. In such patients, we have often withheld anticoagula-
ion with heparin for 48 to 72 hours, until all mediastinal
leeding resolves. Even so, in our current study, we did not
ave any pump malfunction due to thrombosis or thrombo-
mbolic events. When anticoagulation was withheld, flows
reater than 4 liters per minute reduced the risk of throm-
osis even in the absence of anticoagulation.
Experience with ECMO has revealed fairly stringent
equirements for anticoagulation and a high incidence of
hrombotic complications when heparin is not used. Be-
ause a majority of these patients on CentriMag support are
lready on IABP support, we continue IABP support in
ddition to biventricular assist device support for 24 to 72
ours to allow for some degree of pulsatile perfusion. Some
eports suggest beneficial effects of afterload reduction on
yocardial recovery and improved end-organ function with
ulsatile flow.24 In our study, we showed that despite the
eed for multiple surgeries (or at least a second operation
or explantation of the temporary VAD system and for
ermanent LVAD implantation), satisfactory results can be
chieved by using CentriMag support as a bridge to explan-
ation, recovery, or permanent LVAD implantation in pa-
ients with refractory cardiogenic shock and MSOF.
The Journal of ThoracicThe recent introduction of percutaneous VADs into the
linical armamentarium has provided yet another option for
atients with cardiogenic shock in select situations. Al-
hough gaining popularity as temporary support during
igh-risk percutaneous coronary interventions, the Tandem-
eart (CardiacAssist Inc, Pittsburgh, Pa) percutaneous
AD has also been successfully used for patients in cardio-
enic shock. Although the primary advantage is the relative
apidity of institution of hemodynamic support, potential
isadvantages include the relative limitation of flow (max-
mum up to 4 liters per minute), thereby restricting its use in
arger patients. Other disadvantages include the lack of
ercutaneous support options for the right ventricle, possi-
ility of cannula dislodgment, lower extremity ischemia,
nd the need for strict anticoagulation.25,26
We believe that a team approach is essential for optimiz-
ng outcomes even before the patient is transferred to the
eferral hospital. Honest communication with the primary
hysicians regarding the options available will help the
amily realize that even with referral to a major tertiary
enter the patient may not survive. As soon as the patient
nd the family arrive, it is essential to clearly depict the long
nd arduous road ahead with all possible scenarios. Under-
tandably, though, the families are almost always in a state
f shock, so exceptional understanding, patience, and time
re necessary in dealing with them.
The limitations of our study are those associated with a
etrospective study involving a relatively small cohort of
atients. Nevertheless, we believe our conclusions are valid:
ur 12 patients had a similar clinical profile and were cared
or using a single algorithm (Figure 1) based on temporary
entriMag support as bridge therapy. We found CentriMag
upport to be safe and cost-effective. It allows for maximal
se of limited resources and has excellent short-term
urvivals.
We thank Mary E. Knatterud, PhD, for editorial assistance.
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